Biomedical subjects

E Arriola

Publications and source records attributed to E Arriola.

2 recordsLinked to original sources

PubMed1995

The changing relationship between health care professionals and the pharmaceutical industry.

Although UCLA had established policies and procedures for visiting pharmaceutical representatives, changes in both the pharmaceutical business environment and in UCLA's physical environment mandated an update. To deal with the changes, a multidisciplinary team comprised of various departmental staff members met to develop a new vendor representative visitation policy that included the practice of drug sample distribution. More stringent registration requirements and shared responsibility for policy enforcement are the key elements of the new policy.

Academic Medical Centers↗

PubMedDate not supplied

Mycophenolate mofetil.

Mycophenolate mofetil is the morpholinoethylester prodrug of mycophenolic acid, an agent that inhibits the proliferation of B and T lymphocytes through noncompetitive, reversible inhibition of inosine monophosphate dehydrogenase, a key enzyme in the de novo synthetic pathway of guanine nucleotides. Currently, mycophenolate mofetil is approved for the prevention of acute renal allograft rejection when given in combination with cyclosporine and steroids. Several studies also demonstrated that the agent is effective in the treatment of refractory rejection in renal, heart, and liver transplant recipients, and may have efficacy in the treatment of chronic rejection as well.

Animals↗